Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03725293 · ClinicalTrials.gov registry record · NA
Midlines and Thrombophlebitis
A NA study, sponsored by Corewell Health East.
- Completed
- Registry status
- NA
- Development phase
- 212
- Enrollment target
NCT03725293: Completed NA study, sponsored by Corewell Health East.
NCT03725293 is a NA study that has completed, run by Corewell Health East. The registered enrollment target is 212 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03725293, a NA study, has completed, sponsored by Corewell Health East.
- COMPLETED
- Registry status
- NA
- Development phase
- 212 participants
- Enrollment target
Study Summary
Peripherally inserted central catheters (PICCs) are central catheters that are placed via peripheral vein under ultrasound guidance and may be used for patients with difficult venous access for long-term central or peripheral infusion therapies as well as central venous pressure monitoring in a critical care setting. Although PICCs provide a great option for some patients, these catheters have known complications including catheter-related bloodstream infection, catheter-related venous thrombosis or clotting, malfunction, and high cost. Midline catheters represent a potentially attractive alternative to PICCs for peripheral infusions. As midlines have increased in popularity and new midlines have been introduced into the market, it is necessary to better understand complication profiles of various midline catheters, as it is likely that all catheters are not created equal. Specifically, the incidence of symptomatic catheter-related thrombosis is of interest. Some midline catheters are coated to provide protection against catheter-related venous thrombosis and/or catheter-related bloodstream infection. The theoretical benefit(s) of these catheters need further validation in human subjects.
Primary Outcome
Number of participants with proven sonographic diagnosis of DVT and/or SVT
Interventions
- DEVICE Angiodynamics BioFlo Midline Catheter
- DEVICE Teleflex Arrowg+ard Blue Advanced Midline Catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2019-01-14 |
| Est. Completion | 2020-11-26 |
| Phase | NA |
What the finished NCT03725293 record still lists
NCT03725293 is an interventional study that assigns participants to a tested intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Angiodynamics BioFlo Midline Catheter is the first listed.
NCT03725293 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03725293 about?
NCT03725293 is a clinical study titled "Midlines and Thrombophlebitis". Peripherally inserted central catheters (PICCs) are central catheters that are placed via peripheral vein under ultrasound guidance and may be used for patients with difficult venous access for long-term central or peripheral infusion therapies as well as central venous pressure monitoring in a crit...
What is the current status of trial NCT03725293?
This trial is currently completed. It is a NA study. The enrollment target is 212 participants. The study started on 2019-01-14. Estimated completion is 2020-11-26.
What interventions are being tested in trial NCT03725293?
The interventions under investigation include: Angiodynamics BioFlo Midline Catheter (DEVICE), Teleflex Arrowg+ard Blue Advanced Midline Catheter (DEVICE).
Who is sponsoring clinical trial NCT03725293?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03725293's enrollment target sits among peer trials
212 489th of 2000 higher than 1,511 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
- NCT06456593 · 212 participants · Phase 2
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI